Financial

· Sales of $18.3 billion reflecting a decline of 10.8%, operational decline of 9.0%* and adjusted operational decline of 8.8%*, primarily driven by the negative impact of the COVID-19 pandemic · EPS of $1.36 decreased 34.6%; adjusted EPS of $1.67 decreased 35.3%*; 2019 included gain from sale of Advanced Sterilization Products (ASP) business · Company increasing Full Year Sales and EPS guidance

· Sales of $20.7 billion reflecting strong growth of 3.3%, operational growth of 4.8%* and adjusted operational growth of 5.6%*, inclusive of the overall estimated negative impact of the COVID-19 pandemic · EPS of $2.17 increased 56.1%; adjusted EPS of $ 2.30 increased 9.5%* · Dividend increase of 6.3% announced · Long term fundamentals remain intact; 2020 guidance lowered to reflect COVID-19 impact and related investments